Based in Pfäffikon in the canton of Schwyz, Spiden, which specializes in non-invasive biomarker measurements, has achieved something of a breakthrough in the area of glucose measurements. With the help of advanced spectroscopy techniques in a wearable device, the Spiden team managed to achieve a MARD (Mean Absolute Relative Difference) of just 9 percent with individual calibration, i.e. the average difference to the gold-standard measurement, further details of which can be found in a press release. This achievement is the latest vital step on the way to a calibration-free and miniaturized device for non-invasive glucose monitoring. As part of a pilot project, Spiden will now carry out measurements at diabetes centers in various countries, before the company ultimately seeks to launch its own wearable on the market.
“This accomplishment reinforces our commitment to launching our own glucose monitoring wearable by the end of 2025, followed by expanding to additional biomarkers”, comments Leo Grünstein, founder and CEO of Spiden, in the press release. He adds: “We aim to help customers around the world take control of their health through non-invasive access to real-time biomarker data and actionable, evidence-based insights to improve their well-being and longevity”.
The company has secured fresh capital of 15 million US dollars to finance additional research and production activities. In addition, Spiden has bolstered its executive management team by bringing on board Chester Chipperfield as Chief Design Officer (formerly of Apple and Tesla) and Ismene Grohmann as Chief Product Officer (previously of Abbotts Consumer Biowearables). Moreover, Prof. Fernando Perez-Cruz, Chief Data Scientist at the Swiss Data Science Center jointly operated by the Swiss Federal Institutes of Technology in Zurich (ETH) and Lausanne (EPFL) is set to join Spiden in the role of Head of Machine Learning Research & AI.
